1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Phase III Data Put Zealand's Dasiglucagon On Track, But Behind Others, For Hypoglycemia Rescue

 
• By Emily Hayes

Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.

Plastic Autoinjector_222700717_1200.jpg
Currently, rescue treatments for severe hypoglycemia need to be reconstituted, but prefilled syringes in autoinjectors may be on the way.

Positive Phase III results across the board for Zealand Pharma AS's dasiglucagon as a ready-to-use prefilled syringe rescue medication for severe hypoclyemia put the drug on track for a US FDA filing in the second half of 2019, but far behind two competing products that are already under review – Eli Lilly & Co.'s needle-free nasal product AMG504-1 and Xeris Pharmaceuticals Inc.'s XeriSol glucagon autoinjector.

Dasiglucagon (glucagon analog stable in liquid formulation) will be delivered in Zealand's ready-to-use HypoPal autoinjector rescue pen

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

More from Therapy Areas

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.